• No results found

PET imaging of P-glycoprotein at the blood-brain barrier with new 18F-tracers

N/A
N/A
Protected

Academic year: 2021

Share "PET imaging of P-glycoprotein at the blood-brain barrier with new 18F-tracers"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

PET imaging of P-glycoprotein at the blood-brain barrier with new 18F-tracers

Savolainen, Heli Anneli

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Savolainen, H. A. (2018). PET imaging of P-glycoprotein at the blood-brain barrier with new 18F-tracers. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Propositions accompanying the dissertation

PET

imaging of P-glycoprotein at the blood-brain barrier

with

new

18

F-tracers

Heli Savolainen

1. P-gp imaging by PET can help to understand the P-gp function and substrate recognition which are not well known and present a major burden in the drug development (Chapters 1 & 6).

2. An advantage of a weak P-gp substrate radiotracer could be to measure both increases and decreases of P-gp function (Chapters 2, 3 & 6).

3. Chronotherapy based on the daily rhythm of P-gp could improve efficacy of pharmaceuticals which are weak P-gp substrates (Chapter 4).

4. Concentration dependent behavior of P-gp tracers should be taken into account in the setup of in vitro assays (Chapter 5).

5. PET tracer development has been focused on P-gp but should be extended to other ABC transporters as well to investigate their overlapping roles.

6. If you are not sure whether to be a chemist, biologist, physicist, pharmacist or medical doctor, choose nuclear medicine, and all of these can be combined.

7. “You only need one very good idea in your life” (Rainer Kneuer). 8. “One never notices what has been done; one can only see what

remains to be done” (Marie Curie).

Referenties

GERELATEERDE DOCUMENTEN

Several P-glycoprotein (P-gp) substrate tracers are available to assess P-gp function in vivo, but attempts to develop a tracer for measuring expression levels of P-gp

Development of novel fl uorine-18 labeled positr on emission tomography tracers to investigate P-glycoprotein at the blood-brain barrier.

Imaging P-glycoprotein: The gatekeeper of the blood-brain barrier: Development of novel fluorine-18 labeled positron emission tomography tracers to investigate P-glycoprotein at

This review discusses the current body of data relating to maturation of human brain P-glycoprotein including transporter expression levels in post-mortem human brain samples, in

AM Karssen, OC Meijer, ICJ Van der Sandt, PJ Lucassen, ECM De Lange, AG De Boer and ER De Kloet (2001) Multidrug Resistance P-Glycoprotein Hampers the Access of Cortisol But Not

The analysis in this thesis tries to uncover how immigration has been securitized in the NSS. Focusing on this policy document to analyze the securitization of immigration as an

Liposomes for drug delivery are often prepared with maleimide groups on the distal end of PEG to enable coupling of homing devices, such as antibodies, or other proteins.. EDTA is

PET studies showed that transport of [ 18 F]5 across the blood- brain barrier was not altered by pre-treatment with the P-gp inhibitor tariquidar, and uptake was significantly lower